When Alzheimers disease was believed to be caused solely by the accumulation of amyloid protein in the brain, pinning all hopes on an amyloid-targeting drug like Aduhelm the first drug approved to treat Alzheimers in 17 years made sense. But newer knowledge that ties Alzheimers to the biology of aging indicates the disease is caused by a combination of age-related changes in the brain that affect different people in different ways.
That means neither Aduhelm nor any anti-amyloid drug on its own will be a cure for the estimated 6.2 million Americans living with Alzheimers. The next phase of research must focus on promising drugs that target a host of underlying pathologies that contribute to Alzheimers.
Today more than ever, research is embracing this new understanding, taking a more diversified multiple shots on goal approach to new drug targets. More than three in four treatments currently in clinical development work against non-amyloid targets. These include drugs to reduce inflammation in the brain, improve blood flow, clear misfolded proteins, improve how the brain metabolizes energy, and more.
advertisement
To complement these pathways, new biomarkers are needed that will give physicians like me the tools needed to zero in on the causes of each patients Alzheimers and tailor combinations to provide precision personalized medicine.
Alzheimers research is notoriously challenging and expensive, outstripping cost estimates for research in most other therapeutic areas. The brain is incredibly complex, and while Alzheimers is the most common cause of dementia, it is not the only one. But Im more optimistic than ever about whats coming down the pipeline because Alzheimers research has moved into a modern era, not only in the breadth of its targets but in its ability to implement more rigorous clinical trials that track and determine the relationship between biomarker and clinical outcomes.
advertisement
If Aduhelm and other anti-amyloid antibodies that follow it are, at best, just one incremental piece of the puzzle, how do the blanks get filled in? For a start, it is time for everyone in the Alzheimers ecosphere to look toward a broader and more diverse approach to curing this devastating disease and speed the development of new, effective therapies to treat and prevent Alzheimers disease and related dementias.
A critical driver of better and faster clinical trials are biomarkers objectively measurable biological and behavioral characteristics that correlate with Alzheimers disease that are essential for improving trial design and quickly advancing the current pipeline of novel targets.
Biomarkers are already being used to great effect in early-stage trials, quickly telling researchers whether an experimental drug is engaging with its intended target in the brain. They are also playing a larger role in later-stage trials, providing better and quicker ways to screen and enroll patients whose Alzheimers disease profile includes the characteristic the experimental drug is meant to work on, and then by providing an easy means for tracking the effects of treatment. Biomarker data from brain amyloid PET scans, for example, provided the primary data for Aduhelms Food and Drug Administration accelerated approval.
Biomarkers are also making their way into clinical practice. Physicians can now use tests of blood and cerebrospinal fluid to measure brain amyloid levels in people experiencing early signs of mild cognitive impairment or dementia. The day will soon come when a simple blood sample, retina scan, or even a smartphone app will be able to identify underlying causes of Alzheimers during a doctor visit, allowing for treatment to be matched to a patients unique pathology.
As more drugs are developed against a wide range of targets, biomarkers must play a bigger role than ever in clinical trials. Researchers worldwide are working toward validating additional blood and other non-invasive tests that can measure brain levels of everything from tau and other toxic proteins to biological indicators of neuroinflammation, synaptic malfunction, and changes in metabolism. These new biomarker tests will be essential for both clinical trials and clinical practice.
Alzheimers researchers need to work together to conduct more biomarker-powered exploratory trials to more quickly and effectively assess whether a drug has promise. By adopting best practices in designing exploratory trials, researchers and companies can be more confident in using their results to make the all-important go/no-go decisions about advancing drugs to larger, later-stage trials.
In 2019, the Alzheimers Drug Discovery Foundation (which I co-founded) and the Association for Frontotemporal Degeneration convened an advisory panel of experts to provide recommendations on ways to optimize the design and application of exploratory trials. The panels recommendations, published last year in the journal Neurology, are designed to improve trial designs and engage patients more efficiently. When it comes to clinical trials, participants are a limited resource, so it is vitally important, especially for rarer forms of dementia, that they are matched to the right trials and that these trials run as efficiently as possible so each patients involvement is valued and maximized.
Policies that support efforts to bring repurposed drugs to the market are also urgently needed. Repurposed drugs start with an advantage because some of the research, including essential information about safety in humans, has already been done. But they are hampered by the economic disadvantage of limited returns on investment.
The pressure from patient advocacy groups for the FDA to approve and for Medicare to cover Aduhelm a drug that was at best only going to have a modest incremental benefit reflects the understandable public hunger for new Alzheimers treatments. It also underscores the urgent need for better ways to get effective drugs to market for the millions living with Alzheimers.
Its encouraging to see broader consensus in the research community for the need to take fresh looks at the biology of aging. In a 2021 Alzheimers Clinical Trials report, the Alzheimers Drug Discovery Foundation analyzed the approximately 120 clinical trials underway that are tackling a variety of age-related pathways.
These efforts will open the doors to new breakthroughs and the kinds of combination therapies that have changed the lives of people with cancer, diabetes, HIV, and other diseases. At this pivotal moment, academia, industry, regulatory agencies, patient advocates, venture philanthropists, and others need to work together as a community to accelerate the move into this new era of treatment possibilities for people with Alzheimers.
Howard M. Fillit is a neuroscientist and geriatrician, the co-founder and chief science officer of the Alzheimers Drug Discovery Foundation, and a clinical professor of geriatric medicine and palliative care, medicine, and neuroscience at the Icahn School of Medicine at Mount Sinai. He reports having consulted for various pharmaceutical companies, including Alector, LifeWorx, Eli Lilly, Otsuka Pharmaceuticals, and others.
See the rest here:
It's time to move past Aduhelm and focus on a broader Alzheimer's drug pipeline - STAT
- Oncology Precision Medicine Market Research, Industry Trends and Global Forecasts, 2035 - Rising Partnership and ... - PR Newswire - March 18th, 2024
- 3 Precision Medicine Stocks That Could Benefit From the Industry's Rise - InvestorPlace - March 18th, 2024
- Prime Editing Approach Provides a Faster, More Effective Way to Screen for Cancer Mutations - Inside Precision Medicine - March 18th, 2024
- Global Genomics Industry Research 2024-2031: Rising Adoption of Personalized Medicines and Gene Therapies ... - PR Newswire - March 18th, 2024
- CAR T-Cell Therapy Successfully Used to Treat Brain Tumors - Inside Precision Medicine - March 18th, 2024
- Revolutionizing Wellness: The Power of Personalised Health Tech - AutoGPT - March 18th, 2024
- Personalized medicine is coming, but who will have access to it? - March 10th, 2024
- Personalized medicine | Definition, Origins, Examples, & Ethical ... - March 10th, 2024
- Innovating for Individual Care: The Impact of USP on Personalized Medicine - March 10th, 2024
- AI and predictive medicine: Recent advances - News-Medical.Net - March 10th, 2024
- Personalized medicine is coming, but who will have access to it? - AAMC - March 10th, 2024
- Why personalized medicine is a business trend to watch in 2024 - HealthLeaders Media - March 10th, 2024
- AI helps cardiologists deliver personalized healthcarebut there is still plenty of work to do - Cardiovascular Business - March 10th, 2024
- Q&A: How AI and wearable technologies are transforming medicine - EMS1.com - March 10th, 2024
- HealthTech Revolution: Wearables, AI, and the Personalized Future of Healthcare - GearBrain - March 10th, 2024
- Redefining Healthcare: The Rise of Personalized Medicine and the Shift from Conventional Care - Medriva - March 10th, 2024
- Dr Kalinsky on Unanswered Questions Regarding Genomic Testing in HR+ Breast Cancer - OncLive - March 10th, 2024
- Chemotherapy Plus High Doses of Radiation Effective for Treating Non-Small Cell Lung Cancer - Inside Precision Medicine - January 17th, 2024
- It's Time to Fully Embrace Precision Medicine's Promise in Pediatrics - Healthcare Innovation - January 17th, 2024
- Special Report: Radiation Oncology Takeaways from RSNA23 - Imaging Technology News - January 17th, 2024
- Advanced Therapeutics Pharmaceutical Outsourcing Market to Surge at a CAGR of 4.4% by 2034 Amid Growing ... - PR Newswire - January 17th, 2024
- Simulations of the human body and advanced data promise more personalized medical treatment - Medical Xpress - January 17th, 2024
- United States Single Cell Genomics and Proteomics Growth Opportunities: The Integration of Multi-Omics Data to Drive ... - PR Newswire - January 17th, 2024
- Advances Usher In Era of Personalized Treatment for Obesity - Gastroenterology & Endoscopy News - January 17th, 2024
- Unveiling the Reality of Personalized Medicine: Yale Study Highlights Limitations in Current Predictive Models - Medriva - January 17th, 2024
- Digital Twins: The Future of Personalized Healthcare - BNN Breaking - January 17th, 2024
- Healthcare in 2024: A Vision of the Future | Future of Healthcare Predictions - Medriva - January 17th, 2024
- Utilization of the microbiome in personalized medicine - Nature.com - December 22nd, 2023
- Focusing on Women's Health - Inside Precision Medicine - December 22nd, 2023
- Revolutionizing Healthcare: Innovations in Regenerative Medicine Offer Hope - Inside Precision Medicine - December 22nd, 2023
- AI in Genomics Market Predicted to Grow at CAGR of 40.6% by 2031, with Revenue $9.8 Billion - PharmiWeb.com - December 22nd, 2023
- Innovative Technologies Transforming Cancer Treatment - BNN Breaking - December 22nd, 2023
- Antisense Oligonucleotides Industry Poised to Reach US$ 5519.6 Million by 2033-FMI Projection - PharmiWeb.com - December 22nd, 2023
- Live Cell Encapsulation Market To Reach USD 313.3 Million at a CAGR of 4% in 2032 - EIN News - April 23rd, 2023
- Cancer Therapeutics and Biotherapeutics Market is estimated to be US$ 506.8 billion by 2032 with a CAGR of - EIN News - April 7th, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 13th, 2023
- Gene Therapy Market Size (USD 46.5 Bn by 2030): A Growing Industry and Its Impact on Healthcare Systems - EIN News - March 13th, 2023
- Translating the Microbiome - Inside Precision Medicine - October 15th, 2022
- Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials - Applied Clinical Trials Online - October 15th, 2022
- Global Cancer/Tumor Profiling Market Research Report to 2027 - Increasing Demand for Personalized Medicine Presents Opportunities -... - October 15th, 2022
- Cambridge biotech raises $168 million to fight cancer and other diseases - The Boston Globe - October 15th, 2022
- Perlmutter Cancer Center Medical Oncologist Provides Personalized Care to People with Breast Cancer - NYU Langone Health - October 15th, 2022
- Concierge Medicine's Continued Rise Illuminated by Specialdocs Consultants at the Industry's Leading Event - PR Newswire - October 15th, 2022
- Hormone Changes: The Star of Every Stage in Women's Sleep - Medscape - October 15th, 2022
- Could Xolair Be the First Biologic Treatment for Food Allergies? - Allergic Living - October 15th, 2022
- Matching Treatments to Your Genes - The Epoch Times - October 15th, 2022
- Global Monoclonal Antibodies (mAbs) Markets, 2018-2021 & 2022-2030 - Increasing R&D Activities Aimed at the Development of Novel Therapeutic mAbs -... - October 15th, 2022
- Xcell Biosciences and aCGT Vector Collaborate to Accelerate Development of Cell and Gene Therapies - Business Wire - October 15th, 2022
- Learn Look Locate Partners with Genetic Testing Leader, Myriad Genetics, in Educational Campaign - PR Newswire - October 15th, 2022
- Important Mission By LG To Reinvent Society With Future Growth - Forbes - October 15th, 2022
- Scientists identify more than 12,000 spots in the human genome associated with height - Inverse - October 15th, 2022
- The future of cancer research | News - ND Newswire - October 15th, 2022
- Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer - PR Newswire - October 15th, 2022
- Call for Accurate Automation in Healthcare Practices to drive the Laboratory Information Systems (LIS) Market | Future Market Insights, Inc. - Yahoo... - October 15th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - Benzinga - October 15th, 2022
- Global Precision Medicine Software Market is projected to witness a healthy growth rate of 10% in the upcoming years - Bio-IT World - July 17th, 2022
- The Single-Cell Analysis Market Size To Almost Double By 2026 Due To A Rising Focus On Personalized Medicine As Per The Business Research Company's... - July 17th, 2022
- Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare - PR Newswire - July 17th, 2022
- Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific... - July 17th, 2022
- New Approaches Needed To Support Digitization Of Healthcare - Forbes - July 17th, 2022
- Outlook on the Microtome Global Market to 2027 - Increasing Demand for Personalized Medicine Presents Opp - Benzinga - July 17th, 2022
- Precision health perspectives - UCI News - July 17th, 2022
- The Worldwide Compound Management Industry is Expected to Reach $1.4 Billion by 2030 - ResearchAndMarkets.com - Business Wire - July 17th, 2022
- Thrive Pet Healthcare and FidoCure Announce An Expansive Pet Precision Health Partnership - Benzinga - Benzinga - July 17th, 2022
- Access to Myriad Genetics GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial - Yahoo... - July 17th, 2022
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -... - July 17th, 2022
- Research Antibodies and Reagents Market worth $16.1 Billion by 2027 Exclusive Report by MarketsandMarkets - Yahoo Finance - July 17th, 2022
- Global Custom Antibody Market Is Expected To Reach USD 742.27 Million At A CAGR Of 10.3% And Forecast To 2029 - Digital Journal - July 17th, 2022
- Personalized Medicine Coalition - Precision Medicine Advocacy and ... - June 8th, 2022
- Precision Medicine | FDA - June 8th, 2022
- Global Precision Medicine Software Market is anticipated to witness a lucrative CAGR of 10% - GlobeNewswire - June 8th, 2022
- Global Biomarkers Markets Research 2022-2027: Increased Adoption of Biomarkers in Personalized Medicine / Focus on Digital Biomarkers / Increased... - June 8th, 2022
- Every patient in this experimental drug trial saw their cancer disappear, researchers say - CBS News - June 8th, 2022
- The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the... - June 8th, 2022
- Can the industry elevate the success rate of cancer trials? - OutSourcing-Pharma.com - June 8th, 2022
- Purdue Polytechnic Institute and Purdue University Global collaborating on partnership with the University of Puerto Rico - Purdue University - June 8th, 2022
- Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions - PR Newswire - June 8th, 2022
- AdhereTech and Massive Bio, Two of NYC Digital Health 100 most Promising Start-Ups, Announce AI-Enabled, Patient-Centric Oncology Solutions... - June 8th, 2022
- Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022 - Endocrinology Network - June 8th, 2022
- PreludeDx Presents New DCISionRT Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting - 69News WFMZ-TV - June 8th, 2022